Wednesday, October 18, 2023
2:00PM – 3:00PM ET
Please note this TeleECHO program is 2:00PM Eastern, 1:00PM Central, 12:00PM Mountain and 11:00AM Pacific.
|Richard F. Dunne, MD, MS
Associate Professor of Medicine
Leader, Gastrointestinal Cancer Unit and Clinical Research Program
Wilmot Cancer Institute
University of Rochester Medical Center
This virtually live educational activity focuses on the care of patients with advanced/metastatic gastric cancer and gastroesophageal junction adenocarcinoma. The education aims to help healthcare professionals improve their ability to evaluate which patient populations may benefit from anti-angiogenic therapy as a second-line treatment for advanced or metastatic gastric and gastroesophageal junction (GEJ) cancers and select appropriate second- and subsequent-line therapy based on clinical practice guidelines and the latest clinical trial findings.
This activity is designed to educate community-based oncologists, oncology nurses, and other healthcare providers involved in the care of patients with advanced/metastatic gastric cancer and gastroesophageal junction adenocarcinoma.
Upon the completion of this program, attendees should be able to:
- Evaluate which patient populations may benefit from anti-angiogenic therapy as a second-line treatment for advanced or metastatic gastric and gastroesophageal junction (GEJ) cancers
- Select appropriate second- and subsequent-line therapy for the management of gastric/GEJ cancers
- Assess clinical trials findings in patients who could benefit from anti-angiogenic treatment for advanced or metastatic gastric and gastroesophageal junction (GEJ) cancers
- Apply clinical practice guidelines for second treatment in patients with advanced and metastatic gastrointestinal cancers to maximize patient outcomes through proper sequencing of therapy
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at [email protected].
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]